Media.Player

Non Insulin Based Type II Diabetes Therapy

技术优势

The researchers have developed novel compositions that have been demonstrated to be safe and effective in an animal model of diabetes (rodent) Can be taken orally unlike insulin, eliminating the need for painful injections As a therapy restoring the body's ability to regulate blood glucose on its own, it will lead to better real time glucose management, alleviating the deleterious health effects of hyperglycemia A metabolic precursor to this molecule has been used for five decades to treat unrelated conditions and has proven itself to be safe and well tolerated by patients Has the potential to eliminate the adverse side effects, like hypoglycemia and weight gain, of most current diabetes therapies

技术应用

A new, non-insulin based therapy for type II diabetes to aid the body's native insulin response to blood glucose levels; may be used independently or in conjunction with other therapies Allows for the use of a radiolabeled variant of the inhibitor to target beta cells in the pancreas to quantify progression of disease based on the degree of radioactive labeling

详细技术说明

One of the factors contributing to type II diabetes is impaired beta cell function and loss of response to hyperglycemic stimulus. This technology is a novel inhibitor of an ATP dependent transporter molecule expressed in beta cells, which is respons...

*Abstract

None

*Inquiry

Peter GolikovColumbia Technology VenturesTel: (212) 854-8444Email: TechTransfer@columbia.edu

*IR

2299

*Principal Investigation

*Publications

Role of vesicular monoamine transporter type 2 in rodent insulin secretion and glucose metabolism revealed by its specific antagonist tetrabenazine. Raffo A, Hancock K, Polito T, Xie Y, Andan G, Witkowski P, Hardy M, Barba P, Ferrara C, Maffei A, Freeby M, Goland R, Leibel RL, Sweet IR, Harris PE. J Endocrinol. 2008 Jul;198(1):41-9.

*Web Links

Patent pending, WIPO: WO/2009/126305Patent pending, WIPO: WO/2008/112278

国家/地区

美国